First-in-class, first-in-human phase I results of targeted agents: Highlights of the 2008 American Society of Clinical Oncology meeting

This review summarizes phase I trial results of 11 drugs presented at the American Society of Clinical Oncology meeting held in Chicago IL from May 30 to June 3rd 2008: BMS-663513, CT-322, CVX-045, GDC-0449, GRN163L, LY2181308, PF-00562271, RAV12, RTA 402, XL765, and the survivin vaccine.

Detalles Bibliográficos
Autores principales: Molckovsky, Andrea, Siu, Lillian L
Formato: Texto
Lenguaje:English
Publicado: BioMed Central 2008
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2647552/
https://www.ncbi.nlm.nih.gov/pubmed/18959794
http://dx.doi.org/10.1186/1756-8722-1-20
_version_ 1782164931106308096
author Molckovsky, Andrea
Siu, Lillian L
author_facet Molckovsky, Andrea
Siu, Lillian L
author_sort Molckovsky, Andrea
collection PubMed
description This review summarizes phase I trial results of 11 drugs presented at the American Society of Clinical Oncology meeting held in Chicago IL from May 30 to June 3rd 2008: BMS-663513, CT-322, CVX-045, GDC-0449, GRN163L, LY2181308, PF-00562271, RAV12, RTA 402, XL765, and the survivin vaccine.
format Text
id pubmed-2647552
institution National Center for Biotechnology Information
language English
publishDate 2008
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-26475522009-02-25 First-in-class, first-in-human phase I results of targeted agents: Highlights of the 2008 American Society of Clinical Oncology meeting Molckovsky, Andrea Siu, Lillian L J Hematol Oncol Review This review summarizes phase I trial results of 11 drugs presented at the American Society of Clinical Oncology meeting held in Chicago IL from May 30 to June 3rd 2008: BMS-663513, CT-322, CVX-045, GDC-0449, GRN163L, LY2181308, PF-00562271, RAV12, RTA 402, XL765, and the survivin vaccine. BioMed Central 2008-10-29 /pmc/articles/PMC2647552/ /pubmed/18959794 http://dx.doi.org/10.1186/1756-8722-1-20 Text en Copyright © 2008 Molckovsky and Siu; licensee BioMed Central Ltd. http://creativecommons.org/licenses/by/2.0 This is an Open Access article distributed under the terms of the Creative Commons Attribution License ( (http://creativecommons.org/licenses/by/2.0) ), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Review
Molckovsky, Andrea
Siu, Lillian L
First-in-class, first-in-human phase I results of targeted agents: Highlights of the 2008 American Society of Clinical Oncology meeting
title First-in-class, first-in-human phase I results of targeted agents: Highlights of the 2008 American Society of Clinical Oncology meeting
title_full First-in-class, first-in-human phase I results of targeted agents: Highlights of the 2008 American Society of Clinical Oncology meeting
title_fullStr First-in-class, first-in-human phase I results of targeted agents: Highlights of the 2008 American Society of Clinical Oncology meeting
title_full_unstemmed First-in-class, first-in-human phase I results of targeted agents: Highlights of the 2008 American Society of Clinical Oncology meeting
title_short First-in-class, first-in-human phase I results of targeted agents: Highlights of the 2008 American Society of Clinical Oncology meeting
title_sort first-in-class, first-in-human phase i results of targeted agents: highlights of the 2008 american society of clinical oncology meeting
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2647552/
https://www.ncbi.nlm.nih.gov/pubmed/18959794
http://dx.doi.org/10.1186/1756-8722-1-20
work_keys_str_mv AT molckovskyandrea firstinclassfirstinhumanphaseiresultsoftargetedagentshighlightsofthe2008americansocietyofclinicaloncologymeeting
AT siulillianl firstinclassfirstinhumanphaseiresultsoftargetedagentshighlightsofthe2008americansocietyofclinicaloncologymeeting

Ejemplares similares